21/23 exons 3-23(NM_175629,NM_022552) EZH2
19/20 exons 2-20(NM_001203248) IDH1 3 exon 4 (R132) IDH2 2 exon 4 (R140) KDM6A (UTX) 19/29 exons 1, 4, 6, 8, 10, 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 5, 7, 11, 15, 16, 21, 22, 25, 26, 27, 33, 35 SUZ12 4/16 exons 2,3,5,16 TET2 7 9/9 exons 1-9 Chromatin Remodelling ATRX 23/34 exons 1, 4, 7, 9, [11] [12] [13] [14] [15] [17] [18] [19] [20] [21] [22] [23] 25, 26, 28, 29, [31] [32] [33] 3, 4, 5, 6, 7, 8 H3F3A (H3. 2, 4, 7, 12, 13, 14, 17, 20, 22 SF1 6/14 exons 2, 4, 6, 7, 8, 9 (NM_001178030) SF3A1 8/16 exons [2] [3] [4] [5] [6] 10, 11, 14 SF3B1 12/25 exons 6, 8, 11, 12, 13, 14, 16, 17, 18, 21, 24 SRSF2 3 amino acid P95 U2AF1 (35) exons 2,6 (codons 34, 157) U2AF2 (65) 3/12 exons 5, 6, 8 ZRSR2 7/11 exons 1, 3, 4, 7, 8, 9 ,11 Ubiquitination CBL 2/16 exons 8,9
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Cell lines
The cell lines MOLM14, MV4-11, THP1 and U937 were cultured in an incubator at 37 0 C in GIBCO TM 1640 RPMI + Glutamax TM medium supplemented with 10% heat inactivated fetal calf serum (GIBCO), 100 U/ml Penicillin, 100 mg/ml Streptomycin.
DNAse-Seq library preparation
DNase-Seq libraries were prepared essentially as previously described (Ptasinska et al., 2014) . To perform this global mapping of DHSs, DNase I digestions of permeabilized cells were performed as previously described (Bert et al., 2007) . In this procedure, live cells were added directly to a solution of DNase I in dilute NP40, digested for 3 min at 22 o C, and the reactions then terminated by addition of SDS to 0.5%. This protocol maximizes the likelihood that transcription factors will remain bound during the digestion period, thereby increasing the probability of detecting DNase I footprints. DNase I (DPFF) was obtained from Worthington Biochemical Corporation and typically used in the range of 2-6 μg/ml using a final 1.5 x 10 7 cells/ml. The DNA digestion extent was comparable in all the generated samples as measured by RT-PCR (Ptasinska et al., 2012) . The resulting cell lysates were then treated with 0.5 mg/ml
Proteinase K overnight at 37 °C, then in 0.2 mg/ml RNAse A for 1 hour at 37 o C. DNA was isolated by phenol/chloroform extraction. Levels of DNase I digestion were assessed using quantitative real-time PCR, measuring the ratio of the presence of known DNase I
hypersensitive regions compared to a more resistant inactive region. Sequences of the PCR primers used for this purpose were, for the active region, TBP promoter 5´-CTGGCGGAAGTGACATTATCAA and 5´-GCCAGCGGAAGCGAAGTTA; and for the inactive region, a region of chromosome 18: 5´-ACTCCCCTTTCATGCTTCTG and 5´-AGGTCCCAGGACATATCCATT. DNase-Seq samples were generated from a size selection of DNase I-digested DNA fragments comprised within a range of 100 to 250 bp (not including linkers) and subjected to library preparation as per manufacturer´s instruction (Illumina).
Libraries were run on Illumina GAIIx, HiSeq 2000 and 2500 sequencers.
Chromatin immunoprecipitation
ChIP-Seq assays were performed essentially as previously described (Ptasinska et al., 2014) .
In this procedure, cells were resuspended in 10 ml of growing medium, and cross-linked with 1% formaldehyde (equivalent to ~0.33 M) for 10 min at RT. The cross-linking reaction was stopped by adding glycine in excess of the formaldehyde to a final concentration of 0.4 M, followed by two washes with ice-cold PBS. Cells were resuspended in 10 ml of ice-cold ChIP buffer A (10 mM HEPES pH 8.0, 10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100, proteinase inhibitor cocktail (Roche UK, Burgess Hill, UK) and 0.1 mM PMSF), incubated for 10 min at 4°C with rotation, and centrifuged 5 min at 500 x g at 4 °C. The pellet was resuspended in 10 ml of ice-cold ChIP buffer B (10 mM HEPES pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.01% Triton X-100, protease inhibitor cocktail and 0.1 mM PMSF), incubated for 10 min at 4 °C with rotation and centrifuged for 5 min at 500 x g at 4 °C. Cells were resuspended in 600 μl of ice-cold ChIP lysis buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1%
Triton X-100, 0.25% SDS, protease inhibitor cocktail and 0.1 mM PMSF), incubated 10 min on ice and sonicated at 5 °C using a Bioruptor™ (Diagenode, Liege, Belgium) to generate fragments an average length of 400-500 bp (10 min with 30 s "ON" and "OFF" cycles, power setting high). The lysates were centrifuged for 5 min at 16,000 x g at 4 °C and the supernatants were diluted with two volumes of ice-cold ChIP dilution buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 7.5% glycerol, protease inhibitor cocktail and 0. The quantitative PCR primers used for Fos and Runx1 ChIP assays had the following sequences.
MDGA1 DHS: GGGTGGCATCTGACTCAAG and ACTCTCCTTCATGGCCTTCC.
C10orf128 DHS1: CAAGGGCCTCTCTTGGGG and GACTGTTCACCCTCCATGCT.
CCNA1 (-14) DHS: ACTACTAACACCAGCTGCTCT and TGGTTAGGGTAAGGGGCATG.
GZMB DHS: GGAATGAGTTAGGGCTGTGAA and TCTTTATGAGGTTCCAGCTGTG.
CSF1R-FIRE DHS: GCCTGACGCCAACAATGTG and GGCAAAGGAGGGAAGTGAGAG.
IVL promoter: GCCGTGCTTTGGAGTTCTTA and CCTCTGCTGCTGCCACTT.
Mutation detection
Targeted exon sequencing of 55 cancer-associated genes was performed by the West Midlands Regional Genetics Laboratory using 1212 pairs of PCR primers, as summarized in Supplemental Table 1 for amplification using a RainDance Technologies platform. The mutation sequence data summarized in Supplemental Data File 1 was analyzed using algorithms to detect either (i) nucleotide variants using the Genome Analysis Toolkit (GATK) (DePristo et al., 2011) or insertions and deletions using Pindel (Ye et al., 2009 ). Mutations were also screened against the COSMIC data base of previously observed mutations (http://cancer.sanger.ac.uk/cosmic/).
FLT3-ITD detection PCR
FLT3-ITD detection on genomic DNA from patient samples was adapted from a technique used to detect FLT3-ITD variants on cDNA (Kelly et al., 2002) using Taq polymerase (Life Technologies). Primers used to detect a wild-type amplicon size of 394 bp were:
FLT3det-FW: GGTGTTTGTCTCCTCTTCATTGT
FLT3det-RV AAAGCACCTGATCCTAGTACCTT
PCR products were separated on a 1.5% agarose gel.
EMSAs
Electrophoretic mobility shift assays were performed using an AP-1 probe as described previously (Cockerill et al., 1993) .
Western blotting
Cells were lysed in RIPA buffer (Cell Signalling). After electrophoresis of protein extracts on polyacrylamide gels, proteins were transferred to nitrocellulose membranes (Thermo 
Gene expression microarray analysis
1-2 μg RNA was isolated from patient and donor samples via Trizol™ extraction. Sizes and quality of RNA preparations were checked using a RNA 6000 Pico Chip with a Bioanalyzer 2100 system (Agilent). 100 ng RNA was labelled with Cyanine 3-CTP according to the sample preparation protocol from Agilent: One-Color Microarray-Based Gene Expression Analysis (Low Input Quick Amp Labeling). Amplified labelled RNA samples were purified by using Qiagen's RNeasy mini spin columns and cRNA quantified by using a Nanodrop spectrophotometer. Hybridisation samples were prepared for a 8-pack microarray using 600 ng cRNA each according to the hybridisation protocol from Agilent: One-Color MicroarrayBased Gene Expression Analysis (Low Input Quick Amp Labeling), loaded onto as 8-pack SurePrint G3 Human GE 8x60K Microarray kit v1 design ID 028004 (Agilent) and hybridized at 65 °C overnight. After washing, microarrays were scanned on an Agilent G2565C
Microarray Scanner using the Profile AgilentG3_GX_1Color for 8x60K microarrays (Dye channel: Green; Scan region: Scan Area (61 x 21.6 mm); Scan resolution (μm): 3; Tiff: 20 bit).
Probe signals were extracted via the Agilent Feature Extraction software (version 10.7.1.1), protocol GE1_107_Sep09, using grid number 028004_D_F_20110325 (SurePrint G3 Human GE 8x60K). Arrays were normalized via quantile normalization in R using the limma package (Smyth et al., 2005) . Transcript annotations were aggregated into unique gene names, whereby the mean of transcripts was computed for genes with more than one transcript.
Genes with log2 intensities greater than 6.5 were considered expressed. Genes were considered enriched over CD34+ PBSC, WT AML and CD14+ PBSC using a two-fold change cutoff. The Pearson correlation matrix for all samples was computed in R and subsequently clustered via hierarchical clustering using cluster 3.0 (de Hoon et al., 2004) , with row, column
Pearson correlation clustering and complete linkage. Heatmap images were generated via Java TreeView (Saldanha, 2004) . For AML/ PBSC fold mRNA signal change heatmaps, expression fold change values were retrieved for each DHS, using values of the closest gene.
Fold change values were sorted by increasing AML/ PBSC DHS fold change and plotted as heatmaps using Java TreeView.
Gene expression analysis by reverse transcriptase quantitative PCR analysis.
Gene expression patterns were confirmed by Real Time PCR analysis as previously described (Ptasinska et al., 2014) . The PCR primers used were as follows:
GAPDH: CCTGGCCAAGGTCATCCAT and AGGGGCCATCCACAGTCTT.
FAM92A1: GGATGCTAGCCGAACAAGTC and ACCTCTAAAGCTTTGCCGTG.
CTSG: TCCTGGTGCGAGAAGACTTTG and GGTGTTTTCCCGTCTCTGGA.
NOV: CACGGCGGTAGAGGGAGATA and GGGTAAGGCCTCCCAGTGAA.
CCNA1: AGCACTTTTGGCCAGAAACC and GCTGAGGTCGATGGGGTATA.
PRTN3: CTCAATGTCACCGTGGTCAC and GGCCACCTGAGTCTCCGAA.
PT4A3: (PRL3): GCTTCCTCATCACCCACAAC and CGGCGTTTTGTCATAGGTCA.
IL2RA: CTGCCACTCGGAACACAAC and CTCGCTTGGTCCACTGGC.
FOXC1: CCCTCTCTTGCCTTCTTCCT and CGTCAGGTTTTGGGAACACT.
RUNX1:
As used previously (Ptasinska et al., 2014) .
DNA methylation array analysis
DNA methylation analysis was performed by Gen-Probe (UK) using an Illumina 450K methylation array kit. Methylation intensities were obtained via Illumina GenomeStudio to process array image files, probeset extraction and normalization. Per promoter intensities were retrieved via the IMA R package (https://www.rforge.net/IMA/index.html). Genome-wide coverage files (where probe data was available) were obtained using custom R and Perl scripts by generating BED files corresponding to intensities for all probes, followed by WIG format conversion.
Bioinformatic analyses
High-throughput sequencing alignment, peak detection and filtering 193, 127, 800 167, 785, 230 31, 577 CD14+ BM 17, 876, 715 11, 277, 407 16, 268 ITD1 496, 164, 295 342, 121, 088 25, 156 ITD2 563, 648, 832 491, 149, 277 24, 362 ITD3 31, 191, 334 22, 512, 783 27, 899 ITD4 45, 626, 146 35, 117, 991 30, 124 ITD5 232, 690, 946 172, 049, 755 26, 127 WT1 173, 684, 899 155, 121, 178 25, 091 WT2 46, 523, 235 34, 921, 707 23, 592 WT3 27, 668, 387 22, 368, 270 26, 510 WT4 33, 683, 955 28, 775, 417 20, 707 WT5 38, 565, 964 33, 615, 251 25, 868 WT8 56, 390, 352 40, 690, 809 37, 406 To generate DHS coverage tracks, aligned reads were processed using a previously described bioinformatics pipeline (Koch et al., 2011) . Briefly, fragment size was estimated using iterative extension, whereby the maximum overlap of reads corresponded to the mean fragment size. Bases showing more than 5 read starts were considered as clonal artifacts and discarded. Reads were subsequently extended to the estimated size and depth coverage was derived by counting the number of reads in 10-bp windows genome-wide as fixed-length WIG files. Peak detection was subsequently carried out using CoCAS following WIG to GFF conversion. Peak detection parameters were set to the signal mean + 2 standard deviation (p≤0.05) for the both peak and extension thresholds. To account for further sequencing and/or repeat artifacts, peaks were cross-checked against an hg18-converted version of the ENCODE blacklist (ENCODE Project Consortium, 2012) via bedtools (Quinlan and Hall, 2010) . Intersecting peaks were discarded as artifacts. Total numbers of peaks are indicated above.
Generation of peak summit unions
For AML vs CD34+ PBSC DHS comparisons, peak summit unions were performed as previously described (Kreher et al., 2014) . Essentially, peaks were annotated to the nearest isoform for which a distance criterion of 5 kb upstream or downstream of the TSS was used to treat peaks as distal or proximal. Distal and proximal peaks were subsequently treated separately. Unions were computed as the concatenation of AML and CD34+ PBSC datasets, with peak summits closer than 400 bp being treated as one same peak. In this case, the average peak summit coordinate was used as the merge of both. DHS coverages were retrieved [-200bp; +200bp] around the union summits using custom Perl scripts. Distributions of coverages were plotted and tested positive for normality via Shapiro-Wilkes normality tests in R. Coverages were consequently normalized via log2 transformation, centre-scaling to the AML dataset and ranked by log2 AML/CD34+ PBSC fold change to account for read depth heterogeneity. To minimize redundancy, further overlaps of merged and other union summits (left as they were during the merging process) within 400 bp resulted in the first one in genomic coordinate order being retained. To avoid error values, values of 0 tags were replaced by 1 prior to log2 transformation. Heatmap images were generated via Java TreeView. Average signal profiles by increasing DHS fold change were computed using a rolling average with a window size of 1500.
DHS clustering
For total DHS clustering, the union of all distal, primary AML (FLT3-ITD, WT) and CD34+
PBSC DHS summits was computed. Tag coverages were recovered [-200 bp to +200bp] around the union of all summits, log2 transformed, center-scaled and expressed as log2 AML/CD34 fold change, with log2 signal intensities of 0 changed to 1. All values were collated into a single ITD2 and ITD3) and selected DHSs that had a two-fold higher AML/PBSC signal ratio. Since for each union, the AML/CD34+ PBSC DHS fold change followed a normal distribution, we used the same two-fold threshold as the cutoff for AML/PBSC under-enrichment. All DHSs in between -1 and 1 log2 fold change were considered as shared between AMLs and CD34+
PBSCs. Per group average profiles for DNase I, ChIP-Seq, motif frequencies, CpG methylation were generated via a previously described R pipeline (Fenouil et al., 2012) .
Microarray gene expression and CpG methylation fold change boxplots were generated using R.
Significance of overlaps
2-way intersection p-values were computed in R using hypergeometric tests in the ChIPpeakAnno package (Zhu et al., 2010) . 3-way intersection p-values were by deriving the distribution of probabilities for intersections of random samples with sizes corresponding to actual samples, via bootstrapping (10,000 iterations). The actual intersection p-value was retrieved by obtaining the p-value corresponding to the overlap in the simulated distribution of probabilities.
Motif discovery and heatmap generation
Motif discovery was performed via the findMotifsGenome function of Homer (Heinz et al., 2010 ) with a window of -200 bp to +200 bp around the summit. Solely de novo motif enrichment was considered to minimize motif redundancy. For composite motifs, motif length optimization was performed for full-length identification. Motif heatmaps were derived via the annotatePeaks function of Homer using all enriched motifs simultaneously, followed by custom Perl scripts to separate motif outputs. Individual motif presence tables were generated for 200 bp upstream and downstream of each summit for every consequtive10 bp windows and sorted by AML/ PBSC DHS fold change. Random occurrences of motifs were computed by performing motif discovery in similarly sized random sets of coordinates.
Motif co-occurrence clustering analysis
Motif co-occurrence clustering was essentially performed as previously described (Ptasinska et al., 2014) . Briefly, digital genomic footprinting outputs from AML and CD34+ PBSC DHS samples were intersected and defined as AML-specific, shared or CD34+ PBSC -specific via the bedtools intersect function. Specific populations were scanned using motif matrices from
Homer, via the annotatePeaks function of Homer. Motif mapping outputs were converted to the BED format. To obtain motif co-occurrence, motifs containing footprints were all intersected using the intersection_matrix function of the pybedtools package (Dale et al., 2011) . We restricted motif selections to those corresponding to TFs that were actually expressed in any of our analyzed cell types. To assess significance with regards to random occurrence in footprints, we sought to estimate over-representation of occurrence as compared to background co-occurrence all footprints. We thus chose the union of AML plus CD34+ PBSC footprints. Background co-occurrence was estimated using bootstrapping (1000 repetitions) of motif mapping and co-association counts (within 50 bp) in randomly selected footprints within the background, using equally sized populations as the original number of specific footprints. Motif mapping was carried out via the annotatePeaks function of Homer, non-redundant, non-composite matrices
Corresponding ChIP-Seq heatmaps
ChIP-Seq tag counts were recovered for 200 bp upstream and downstream of merged DHS union summits via custom Perl scripts. Rows were reordered accordingly for each DHS union.
Heatmap images were generated via Java TreeView. Average profiles by increasing AML/ PBSC DHS signal ratio were computed in R using a moving average with a window size of 1500.
Digital genomic footprinting
High-depth DHS datasets (ITD1, ITD2, and CD34+ PBSC) were aligned as described and subsequently converted to the sorted BAM format, whereby an index was generated via samtools (Li et al., 2009 ). DHSs were specifically identified using the findPeaks function of Homer. Digital genomic footprinting was performed using the Wellington_footprints function of the Wellington algorithm (Piper et al., 2013) on AML and CD34+ PBSC DHSs. DHS cut coverages, strand imbalance heatmaps and average profiles were generated using the dnase_wig_tracks, dnase_to_javatreeview and dnase_average_profile functions of Wellington. AML-specific footprints were identified by computing differences in footprinting occupancy scores at given genomic coordinates for both test and comparator datasets, then merging reads from each and estimating the footprinting score of merged reads against the randomized comparator dataset as a percentile. Heatmaps images were obtained via Java TreeView. For heatmaps showing the presence of footprinted motifs, sorted by AML/PBSC footprint probability fold change, motif discovery results were converted to BED files and subsequently intersected with digital footprinting results using the bedtools intersect function.
Footprinted motifs were mapped back to the AML/ PBSC DHS unions by calculating the distance of each footprinted motif to the merged DHS summit BED entry, whereby infinity was used if a DHS did not intersect with any footprinted motif. Resulting outputs were converted as distances to summit, and subsequently expressed as tables 200 bp upstream and downstream of each summit using custom Perl scripts, whereby motif frequencies were computed every 10 bp for all regions, ordered according to fold changes. Heatmaps were generated via Java Treeview. Motif densities were computed relative to each summit, where distances used were that between the start of each motif (regardless of the strand) and the summit.
Accession numbers
The DNA sequence files associated with this study have been deposited as a superseries in the Gene Expression Omnibus data base (accession number GSE64874). This superseries encompasses individually accessible DNase-Seq datasets GSE64864), ChIP-Seq datasets (GSE64862) and microarray expression datasets (GSE64873)
Public datasets
The previously published Runx1 ChIP-Seq dataset in CD34+ PBSC (Ptasinska et al., 2014) was retrieved from the Gene Expression Omnibus (GEO), accession GSM1466000. Following SRA to FASTQ conversion via the SRA toolkit (version 2.4.7), this sample was processed as other high throughput sequencing samples. ENCODE DNase I chromatin accessibility datasets for CD34+ stem cells, mobilized CD34+ PBSCs and CD14+ cells were retrieved from GEO accessions GSM595919, GSM530652 and GSM701541, respectively (Bernstein et al., 2010; Neph et al., 2012) . These samples were processed similarly as above.
Expression profiles in larger patient cohort datasets
Gene expression results from large patient cohort datasets (Cancer Genome Atlas Research Network, 2013; Verhaak et al., 2009) were downloaded from the Leukemia Gene Atlas (Hebestreit et al., 2012) as text files. For data from Verhaak et al., patients were split according to their FLT3-ITD mutational status; for data from the Cancer Genome Atlas Research Network, since only the presence of mutations in the FLT3 gene was screened, patients were split according to their FLT3 mutational status. Probeset expression data was aggregated into per gene average expression data in the case of genes spanning more than one probe.
Expression values for 134 and 77 FLT3-ITD up-and down-regulated genes identified in this study were subsequently retrieved using the merge function in R. Boxplots for individual genes and gene averages were plotted using R.
